Products - Diabetes | Topic | NICE

Showing 9 products

Date | Sort by Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
Status: In developmentRemove ‘Status: In development’ filter

Dapagliflozin, in combination with insulin, for treating type 1 diabetes [ID1478]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
28 August 2019
Diabetic foot infection: antimicrobial prescribing
Status:
In development
Programme:
NICE guideline
Expected publication date:
11 October 2019
Sotagliflozin, in combination with insulin, for treating type 1 diabetes [ID1376]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
18 December 2019
Diabetic retinopathy - ruboxistaurin [ID382]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Macular oedema (diabetic) - pegaptanib sodium [ID452]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Diabetes - buccal insulin [ID311]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (part review of TA301) [ID1421]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC